Cover Image
市場調查報告書

細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 358696
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析 Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018
出版日期: 2018年03月13日 內容資訊: 英文 106 Pages
簡介

本報告提供全球各國治療細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要的疾病及藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 臨床實驗後期階段的產品
    • 臨床實驗初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13) 治療藥的開發企業
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Pharma SA
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • 藥物簡介
    • Adxs-LmddA159
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • AG-1101
    • APR-017
    • APR-246
    • ATRN-502
    • cenersen sodium
    • contusugene ladenovec
    • COTI-2
    • D-12PGJ3
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
    • Gene Therapy to Activate p53 for Oncology
    • KM-3174
    • MHY-449
    • MJ-05
    • MX-225
    • N-2
    • Oncolytic Viruses to Activate p53 for Oncology
    • OSE-2101
    • p28
    • QPAL-1
    • QPI-1002
    • Recombinant Protein to Activate p53 for Oncology
    • SGT-53
    • SL-801
    • Small Molecule to Activate p53 for Cancer
    • Small Molecules to Activate p53 for Cancer and Viral Infections
    • Small Molecules to Activate p53 for Melanoma
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology
    • ZMC-1
  • 開發暫停的計劃
  • 開發中止的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1351TDB

Summary:

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation.

Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 22 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 3 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Small-Cell Lung Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Effects, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Hematological Tumor, Hepatic - Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma and Solid Tumor.

The latest report Cellular Tumor Antigen p53 - Pipeline Review, H1 2018, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview
    • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
    • Aprea AB
    • CanBas Co Ltd
    • Cotinga Pharmaceuticals Inc
    • Innovation Pharmaceuticals Inc
    • ORCA Therapeutics BV
    • OSE Immunotherapeutics
    • Quark Pharmaceuticals Inc
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
    • APR-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AU-14022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBS-9106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • contusugene ladenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-12PGJ3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MHY-449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MJ-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-2101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPAL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGT-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZMC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
      • Feb 08, 2018: Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
      • Jan 25, 2018: Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS One
      • Jan 25, 2018: OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications
      • Dec 27, 2017: Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
      • Dec 19, 2017: Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
      • Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
      • Nov 15, 2017: Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
      • Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference
      • Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting
      • Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting
      • Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer
      • Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
      • Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
      • Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Aprea AB, H1 2018
  • Pipeline by CanBas Co Ltd, H1 2018
  • Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
  • Pipeline by Innovation Pharmaceuticals Inc, H1 2018
  • Pipeline by ORCA Therapeutics BV, H1 2018
  • Pipeline by OSE Immunotherapeutics, H1 2018
  • Pipeline by Quark Pharmaceuticals Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Dormant Products, H1 2018 (Contd..3), H1 2018
  • Dormant Products, H1 2018 (Contd..4), H1 2018
  • Dormant Products, H1 2018 (Contd..5), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top